ArticleOpen forum infectious diseases2019
Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Characterizing blood pressure trajectories in people living with HIV following antiretroviral therapy: A systematic review.HIV medicine · 2023Pooled it
- Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation.Annals of epidemiology · 2026Trial
- Incident hypertension among adults on ART in Malawi: a nested cohort study.BMC infectious diseases · 2025Trial
- Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.AIDS research and therapy · 2025Trial
- Longitudinal Serum Metabolomic Signatures Related to Integrase Strand Transfer Inhibitors-Associated Weight Gain in Women with HIV Enrolled in the MACS/WIHS Combined Cohort Study.The Journal of infectious diseases · 2026Article
- Challenges in HIV care at a tertiary hospital repurposed for COVID-19: an observational study (2019-2022).BMC infectious diseases · 2025Observational
- Prevalence and associated factors of overweight and obesity among people living with HIV on antiretroviral therapy in a national hospital in Benin.Scientific reports · 2025Article
- The heart and HIV therapy: exploring the dual cardiovascular impact of antiretroviral treatment - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors.The Journal of antimicrobial chemotherapy · 2025Article
- Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.Journal of the International AIDS Society · 2024Article
- Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism.Current HIV/AIDS reports · 2024Review
- Association of Integrase Strand Transfer Inhibitor-Based Antiretroviral Therapy With Blood Pressure and Sustained Hypertension in People With Human Immunodeficiency Virus.American journal of hypertension · 2024Article
- Observational
- Cardiometabolic Health in Pregnancy and Postpartum: Findings From a Prospective Cohort Study in South Africa.Open forum infectious diseases · 2024Article
- Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.The Pan African medical journal · 2024Article
- Review
- Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.Journal of the International AIDS Society · 2023Article
- Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa.EClinicalMedicine · 2023Article
- Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.HIV medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntegrase strand transfer inhibitors (INSTI) have been associated with weight gain, but their effect on short-term overweight and obesity incidence, blood pressure (BP), and metabolic markers has not been described in treatment-naïve people with HIV(PWH).
methodMedical records of treatment-naïve persons starting antiretroviral therapy (ART) at the HIV Clinic of University Hospital of Elche, Spain, between January 2007 and July 2019 were reviewed retrospectively. Standard procedures included measurements of weight, BP, and metabolic assessment. Data at baseline, 48, 72, and 96 weeks post ART initiation were analyzed. We used Cox mixed-effects model to generate predictions of body mass index (BMI) over time and generalized additive mixed models to relax the linearity assumptions and generate 95% confidence intervals in the multivariable adjustment.
resultsAmong 219 (median age, 44.0 years; interquartile range [IQR], 37.0-53.5; 46 females) participants. Baseline weight mean (standard deviation) was 70.4 (13.7) kg without difference between regimens; 66% had a BMI <25 kg/mt
conclusionsIntegrase strand transfer inhibitors-based ART was associated in the short-term with a greater risk of overweight and obesity and SBP elevation. Patients developing overweight and obesity increased low-density lipoprotein cholesterol with no other metabolic disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.